Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 107 Carcinoma, Renal Cell 74 Neoplasm Metastasis 48 Neoplasms 37 Neuroendocrine Tumors 35 Kidney Neoplasms 27 Recurrence 19 Tuberous Sclerosis 18 Carcinoma, Non-Small-Cell Lung 17 Prostatic Neoplasms 16 Triple Negative Breast Neoplasms 15 Lymphoma 15 Lymphoma, Mantle-Cell 14 Lymphoma, Large B-Cell, Diffuse 14 Head and Neck Neoplasms 14 Glioblastoma 14 Carcinoma, Hepatocellular 14 Colorectal Neoplasms 13 Stomach Neoplasms 12 Lung Neoplasms 12 Leukemia, Lymphocytic, Chronic, B-Cell 12 Hodgkin Disease 12 Brain Neoplasms 12 Sarcoma 11 Precursor Cell Lymphoblastic Leukemia-Lymphoma 11 Pancreatic Neoplasms 11 Glioma 11 Waldenstrom Macroglobulinemia 10 Lymphoma, Follicular 10 Carcinoma, Neuroendocrine 10

Interventions

pembrolizumab 2 Pemetrexed 2 nilotinib 1 glutathione pegylated liposomal doxorubicin 1 ficlatuzumab 1 Zoledronic Acid 1 Trastuzumab 1 Radiosurgery 1 MRX-2843 1 Everolimus 1 Electrochemotherapy 1 Denosumab 1 Cisplatin 1 Carboplatin 1 Bleomycin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplastic Processes × Everolimus × Clear all

NCT01178151 2015-04-22

EVAMP

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 2 Withdrawn

Neoplasm Metastasis, Neoplasms, Neoplastic Processes, Peutz-Jeghers Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡